Semaglutide & cardiovascular outcomes: the SELECT trial and the cardiometabolic case
A 20% reduction in heart attacks and strokes in SELECT. Blood pressure, lipids, and inflammation across STEP. And why the cardiovascular evidence changes the cost and coverage argument.
SELECT: cardiovascular outcomes for a weight-loss drug
Published in 2023, SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, but without diabetes, and followed them for a mean of about 40 months. Semaglutide 2.4 mg reduced the primary composite endpoint — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — by 20% (hazard ratio 0.80) versus placebo. This was the first trial to show a weight-management GLP-1 prevents cardiovascular events, independent of diabetes.
Blood pressure, lipids, and inflammation
Beyond events, semaglutide moves cardiometabolic markers. Across the STEP program and real-world cohorts, patients saw meaningful reductions in systolic blood pressure (roughly 5–6 mmHg), triglycerides, LDL cholesterol, HbA1c, and C-reactive protein — an inflammation marker linked to cardiovascular risk. These changes are largely weight-loss mediated.
Why SELECT changes the insurance argument
Before SELECT, obesity was often treated by insurers as a lifestyle condition. Post-SELECT, semaglutide has level-1 evidence for preventing heart attacks and strokes. If you have established cardiovascular disease alongside overweight or obesity, your prescriber can now cite a 17,000-patient trial showing a 20% event reduction to a medical reviewer — the single most powerful lever in many prior-authorization requests. Our FAQ hub covers coverage basics.
The financial case for treating obesity as cardiovascular disease
A cardiovascular event — heart attack or stroke — can cost tens of thousands of dollars acutely and far more over time. A patient who avoids one is generating savings that dwarf even brand semaglutide's ~$16,000 annual cost, let alone a $1,740 flat-rate compounded program. This is the argument payers are slowly accepting: treating obesity aggressively can be cheaper than treating its downstream disease.
What SELECT does and doesn't prove
SELECT was a landmark because it moved semaglutide from "helps you lose weight" to "prevents cardiovascular events," but reading it precisely matters. The trial enrolled people who already had established cardiovascular disease plus overweight or obesity, and specifically excluded people with diabetes. That means its 20% event reduction applies most directly to secondary prevention — reducing a second event in people who've already had cardiovascular disease — rather than to primary prevention in otherwise healthy people carrying extra weight. Extrapolating the benefit beyond the studied population is a reasonable hypothesis, not a proven fact.
It's also worth being clear about the mechanism question SELECT leaves partly open. The event reduction is larger than weight loss alone would fully explain in some analyses, suggesting semaglutide may have cardiovascular benefits beyond the pounds lost — through effects on inflammation, blood pressure, and the vasculature directly. The trial wasn't designed to fully disentangle these pathways, so the honest statement is that the benefit is real and clinically meaningful, while its full explanation is still being worked out.
For a reader making a purchasing and coverage decision, the practical takeaways are narrower and firmer: if you have established cardiovascular disease and qualifying weight, SELECT gives your prescriber strong, citable evidence for a prior-authorization request, and it strengthens the general case for treating obesity as a medical rather than cosmetic condition. And critically, SELECT studied the FDA-approved brand product — its cardiovascular findings cannot simply be assumed to transfer to compounded semaglutide, which has no comparable outcomes trial. That distinction is exactly the kind of thing a careful buyer should keep in view.
Frequently asked questions
What did the SELECT trial find?
SELECT (17,604 patients, ~40 months) found semaglutide 2.4 mg reduced major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — by 20% (HR 0.80) versus placebo in adults with established cardiovascular disease and overweight/obesity, without diabetes.
Does semaglutide lower blood pressure?
Across the STEP program and real-world data, semaglutide produced systolic blood pressure reductions of roughly 5–6 mmHg, largely attributed to weight loss, along with improvements in lipids and HbA1c.
Is semaglutide good for the heart?
In the SELECT trial, semaglutide reduced cardiovascular events by 20% in people with established cardiovascular disease and overweight/obesity. Individual suitability for anyone with heart disease is a clinical decision for a cardiologist and prescriber.
How does cardiovascular disease affect semaglutide insurance coverage?
Established cardiovascular disease is a recognized comorbidity that can support prior authorization for Wegovy. Post-SELECT, framing the request around cardiovascular risk reduction is an increasingly effective strategy.
References
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023.
- Wilding JPH, et al. STEP 1 cardiometabolic secondary endpoints. N Engl J Med. 2021.
- Novo Nordisk. Wegovy Prescribing Information — cardiovascular indication.
- Semaglutide Price Guide FAQ and July 2026 price report.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.